Revumenib
SNDX-5613-0705
Phase 1 small_molecule completed
Quick answer
Revumenib for Acute Leukemia is a Phase 1 program (small_molecule) at Syndax Pharmaceuticals Inc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Syndax Pharmaceuticals Inc
- Indication
- Acute Leukemia
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed